In this case, dupilumab discontinuation was initially considered, but, in order to avoid resuming steroids and since previous anti-IL-5 mepolizumab monotherapy had failed to control asthma symptoms, it was chosen not to stop dupilumab and to add-on benralizumab. The gene discussed is IL5; the disease is asthma.